Toward a translational approach to targeting the endocannabinoid system in posttraumatic stress disorder: A critical review of preclinical research
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Despite the lack of clinical research, marijuana and synthetic cannabinoids have been approved to treat posttraumatic stress disorder (PTSD) in several states in the United States. This review critically examines preclinical research on the endocannabinoid system (ECS) in order to evaluate three key questions that are relevant to PTSD: (1) Does ECS dysfunction impact fear extinction? (2) Can stress-related symptoms be prevented by ECS modulation? (3) Is the ECS a potential target for enhancing PTSD treatment? Disruption of the ECS impaired fear extinction in rodents, and ECS abnormalities have been observed in PTSD. Targeting fear memories via the ECS had mixed results in rodents, whereas augmented cannabinoid receptor activation typically facilitated extinction. However, the translational value of these findings is limited by the paucity and inconsistency of human research. Further investigation is necessary to determine whether incorporating cannabinoids in treatment would benefit individuals with PTSD, with cautious attention to risks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fear memories require protein synthesis in the amygdala for reconsolidation after retrieval
Nader, K., Schafe, G. E., & Le Doux, J. E. (2000) · Nature · doi:10.1038/35021052 · Cited by 2,706 · cited 1×
“When a memory is reactivated by a cue or context, it is subsequently restored through a time-limited, protein-synthesis dependent process termed reconsolidation (Nader & Hardt, 2009; Nader, Schafe, & Le Doux, 2000; Tronson & Taylor, 2007).”
BackgroundCannabis use and risk of psychotic or affective mental health outcomes: a systematic review.
Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61162-3 · Cited by 2,224 · cited 1×
“…has been associated with a range of poor psychosocial outcomes (Hall, 2014) as well as symptoms of mood, anxiety, and psychotic disorders (Crippa et al., 2009; Moore et al., 2007), suggesting complex effects that require careful assessment of risk alongside any examination of potential benefits.”
BackgroundThe Neurocircuitry of Fear, Stress, and Anxiety Disorders
Shin, L. M., & Liberzon, I. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.83 · Cited by 2,083 · cited 1×
“…2003; Jovanovic & Ressler, 2010), synaptic (Amano, Unal, & Paré, 2010; Myers & Davis, 2007), neurocircuitry (Rauch, Shin, & Phelps, 2006; Shin & Liberzon, 2010), and behavioral (Delamater, 2004) levels, and extensively studied in the context of anxiety in humans (Bitterman & Holtzman,…”
BackgroundThe endogenous cannabinoid system controls extinction of aversive memories
Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., Hermann, H., Tang, J., Hofmann, C., Zieglgänsberger, W., et al. (2002) · Nature · doi:10.1038/nature00839 · Cited by 1,728 · cited 8×
“However, these deficits were not present in animals that received treatment prior to fear acquisition but not during extinction (Marsicano et al., 2002; Reich et al., 2008; Suzuki et al., 2004), suggesting that only blockade of CB1 receptors specifically during extinction training impaired…”
BackgroundInfluentialNeural Mechanisms of Extinction Learning and Retrieval
Quirk, G. J., & Mueller, D. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301555 · Cited by 1,645
Fear Extinction as a Model for Translational Neuroscience: Ten Years of Progress
Milad, M. R., & Quirk, G. J. (2012) · Annual Review of Psychology · doi:10.1146/annurev.psych.121208.131631 · Cited by 1,466 · cited 1×
“…(Amano, Unal, & Paré, 2010; Myers & Davis, 2007), neurocircuitry (Rauch, Shin, & Phelps, 2006; Shin & Liberzon, 2010), and behavioral (Delamater, 2004) levels, and extensively studied in the context of anxiety in humans (Bitterman & Holtzman, 1952; Lissek et al., 2005; Milad & Quirk, 2012).”
BackgroundRauch, S. L., Shin, L. M., & Phelps, E. A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.06.004 · Cited by 1,397 · cited 1×
“…Annas, Neale, Kendler, & Fredrikson, 2003; Jovanovic & Ressler, 2010), synaptic (Amano, Unal, & Paré, 2010; Myers & Davis, 2007), neurocircuitry (Rauch, Shin, & Phelps, 2006; Shin & Liberzon, 2010), and behavioral (Delamater, 2004) levels, and extensively studied in the context of anxiety in…”
Myers, K. M., & Davis, M. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001939 · Cited by 1,277 · cited 1×
“…been examined at the genetic (Hettema, Annas, Neale, Kendler, & Fredrikson, 2003; Jovanovic & Ressler, 2010), synaptic (Amano, Unal, & Paré, 2010; Myers & Davis, 2007), neurocircuitry (Rauch, Shin, & Phelps, 2006; Shin & Liberzon, 2010), and behavioral (Delamater, 2004) levels, and extensively…”
Memory Reconsolidation and Extinction Have Distinct Temporal and Biochemical Signatures
Suzuki, A., Josselyn, S. A., Frankland, P. W., Masushige, S., Silva, A. J., & Kida, S. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.5491-03.2004 · Cited by 1,127
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61721-8 · Cited by 1,097 · cited 1×
“…of the CB1 antagonist rimonabant for the treatment of obesity found an increased risk of adverse psychiatric outcomes, including suicidal ideation (Christensen, Kristensen, Bartels, Bliddal, & Astrup, 2007; Rucker, Padwal, Li, Curioni, & Lau, 2007), which may indicate a pharmacologic effect of…”
Background
Cited by
Cannabidiol as a Potential Treatment for Anxiety Disorders
Blessing, E. M., Steenkamp, M. M., Manzanares, J., & Marmar, C. R. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0387-1 · Cited by 695
Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review
Sarris, J., Sinclair, J., Karamacoska, D., Davidson, M., & Firth, J. (2020) · BMC Psychiatry · doi:10.1186/s12888-019-2409-8 · Cited by 253
Ruglass, L. M., Lopez-Castro, T., Papini, S., Killeen, T., Back, S. E., & Hien, D. A. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000462977 · Cited by 105
Self-citationAddictive potential of novel treatments for refractory depression and anxiety
Kolar, D. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s167538 · Cited by 37
“There are single reports of marijuana being used successfully to treat PTSD symptoms.(39) This is somewhat surprising because substance abuse, including cannabis use disorder, is a common psychiatric comorbidity/complication in patients with PTSD, but now we have the situation where cannabis is being used for PTSD tre…”
Background
Metadata
- Authors
- Papini, S., Sullivan, G. M., Hien, D. A., Shvil, E., & Neria, Y.
- Venue
- Biological Psychology
- Publisher
- Elsevier BV
- Published
- 2015-01
- Volume
- 104
- Pages
- 8-18
- ISSN
- 0301-0511 (ISSN-L)
- OpenAlex
- W1973521514
- Cited by
- 36
- References
- 63
- FWCI
- 3.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Toward a translational approach to targeting the endocannabinoid system in posttraumatic stress disorder: A critical review of preclinical research. https://app.cochat.ai/papers/10.1016/j.biopsycho.2014.10.010
- The paper
- Papini, S., Sullivan, G. M., Hien, D. A., Shvil, E., & Neria, Y. (2015). Toward a translational approach to targeting the endocannabinoid system in posttraumatic stress disorder: A critical review of preclinical research. Biological Psychology. https://doi.org/10.1016/j.biopsycho.2014.10.010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.